This result is in line with the findings of other systematic reviews.24–26 However, another meta-analysis found a significantly higher incidence of bleeding (two trials, OR= 2.72 [95% CI: 1.05–7.01]; P= 0.039) with factor Xa inhibitors, relative to LMWH.27 Importantly, the bleeding outcome in comparison to LMWH was the result of pooled data from nonspecific cancer patients. The gene discussed is F10; the disease is cancer.